Drug Profile
OMX 4.80P
Alternative Names: OMX-4.80PLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Omniox
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
- 21 Jul 2016 Preclinical trials in Cancer in USA (IV)